Published in Cancer Res on November 15, 2011
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer | NCT01553851
A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin Cancer Res (2014) 1.20
Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer. Oncotarget (2016) 1.02
CD44 gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan. PLoS One (2014) 0.92
Perivascular stem cell niche in head and neck cancer. Cancer Lett (2012) 0.90
JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers. Cancer Res (2016) 0.88
mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. Oncotarget (2015) 0.87
CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma. Oncotarget (2014) 0.85
Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res (2014) 0.85
Stem-like cells and therapy resistance in squamous cell carcinomas. Adv Pharmacol (2012) 0.83
Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. Cancer Immunol Res (2016) 0.82
CD26 expression on T-anaplastic large cell lymphoma (ALCL) line Karpas 299 is associated with increased expression of versican and MT1-MMP and enhanced adhesion. BMC Cancer (2013) 0.81
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal. Front Oncol (2016) 0.80
WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition. J Exp Clin Cancer Res (2016) 0.80
Sulforaphane inhibits invasion via activating ERK1/2 signaling in human glioblastoma U87MG and U373MG cells. PLoS One (2014) 0.80
Induction of cell cycle arrest and apoptosis in caspase-3 deficient MCF-7 cells by Dillenia suffruticosa root extract via multiple signalling pathways. BMC Complement Altern Med (2014) 0.80
Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays. J Immunol Methods (2016) 0.79
Uncovering the dual role of RHAMM as an HA receptor and a regulator of CD44 expression in RHAMM-expressing mesenchymal progenitor cells. Front Cell Dev Biol (2015) 0.77
Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. Cancer Immunol Res (2016) 0.77
Genomic analysis to define molecular basis of aggressiveness in a mouse model of oral cancer. Genom Data (2015) 0.76
ESM1 mediates NGFR-induced invasion and metastasis in murine oral squamous cell carcinoma. Oncotarget (2016) 0.75
Identification and characterization of Dicer1e, a Dicer1 protein variant, in oral cancer cells. Mol Cancer (2014) 0.75
Hyaluronan induces odontoblastic differentiation of dental pulp stem cells via CD44. Stem Cell Res Ther (2016) 0.75
Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. Oral Oncol (2017) 0.75
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight (2017) 0.75
Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. Oncotarget (2017) 0.75
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A (2007) 11.94
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol (2003) 9.13
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature (1986) 6.14
Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst (1998) 5.05
Recent advances in head and neck cancer. N Engl J Med (2008) 5.05
Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med (2000) 3.84
Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell (2008) 3.75
CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev (2002) 3.07
ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell (2010) 3.03
CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest (2011) 2.90
Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck (2010) 2.51
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck (2007) 2.49
Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev (2006) 2.46
Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol (2008) 2.21
Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol (2008) 2.18
Experimental carcinogenesis in the cheek pouch of the Syrian hamster. J Dent Res (1954) 2.03
CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res (2010) 1.97
Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest (2009) 1.95
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol (2010) 1.92
Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities. Clin Cancer Res (2009) 1.88
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal (2011) 1.77
Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res (2009) 1.74
Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle (2011) 1.70
Oral cancer. Mayo Clin Proc (2007) 1.67
A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev (2006) 1.60
Survival following primary surgery for oral cancer. Oral Oncol (2008) 1.50
Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol (2011) 1.44
High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer (1991) 1.41
The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J Virol (2007) 1.40
Xenograft models of head and neck cancers. Head Neck Oncol (2009) 1.37
Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res (2001) 1.36
Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head Neck (2011) 1.35
Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol Cell Biol (2006) 1.34
Mek1 alters epidermal growth and differentiation. Cancer Res (2004) 1.33
Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene (2003) 1.32
Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2003) 1.30
A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res (1993) 1.26
The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines. Oral Oncol (2006) 1.20
Chemical carcinogenesis models for evaluating molecular-targeted prevention and treatment of oral cancer. Cancer Prev Res (Phila) (2009) 1.12
ABIN-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions. Mol Cell Biol (2007) 1.12
Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene (2009) 1.01
Animal models of cancer in the head and neck region. Clin Exp Otorhinolaryngol (2009) 0.95
Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. Mol Cancer Res (2007) 0.92
Regulation of CD44 gene expression by the proinflammatory cytokine interleukin-1beta in vascular smooth muscle cells. J Biol Chem (1998) 0.90
Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. Int J Cancer (1999) 0.85
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature (2005) 7.40
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 4.98
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A (2012) 4.20
A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis (2012) 2.58
Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res (2006) 2.56
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother (2008) 2.38
HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A (2008) 2.31
Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck (2011) 2.30
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother (2012) 2.17
MR imaging of the spleen: spectrum of abnormalities. Radiographics (2005) 2.16
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer (2002) 2.16
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
Stereotactic laser ablation of high-grade gliomas. Neurosurg Focus (2014) 2.13
HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol (2009) 2.08
Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother (2005) 2.05
Human papillomavirus-positive basaloid squamous cell carcinomas of the upper aerodigestive tract: a distinct clinicopathologic and molecular subtype of basaloid squamous cell carcinoma. Hum Pathol (2010) 2.01
High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol (2011) 2.00
Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A (2010) 1.91
Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy (2003) 1.85
Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother (2005) 1.69
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient. Antimicrob Agents Chemother (2008) 1.67
Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res (2004) 1.65
Adenosquamous carcinoma of the head and neck: relationship to human papillomavirus and review of the literature. Head Neck Pathol (2011) 1.61
A retrospective comparison of 2 methods of intraoperative margin evaluation during partial nephrectomy. J Urol (2008) 1.49
Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. Med Mycol (2010) 1.45
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.44
Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope (2010) 1.42
Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res (2006) 1.39
Adrenal masses: mr imaging features with pathologic correlation. Radiographics (2004) 1.38
Transoral laser microsurgery (TLM) +/- adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope (2009) 1.37
IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. J Immunol (2002) 1.36
Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol (2005) 1.33
Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother (2012) 1.31
Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother (2009) 1.31
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res (2010) 1.31
Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J Immunol (2009) 1.30
Giant cell tumor of the thoracic spine: case report and review of the literature. Surg Neurol (2008) 1.22
Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation (2008) 1.22
Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med (2014) 1.21
Papillary squamous cell carcinoma of the head and neck: clinicopathologic and molecular features with special reference to human papillomavirus. Am J Surg Pathol (2013) 1.18
Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep (2013) 1.17
MRI of adrenal and extraadrenal pheochromocytoma. AJR Am J Roentgenol (2005) 1.16
A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. Int J Cancer (2012) 1.11
Utility of high molecular weight cytokeratins, but not p63, in the differential diagnosis of neuroendocrine and basaloid carcinomas of the head and neck. Hum Pathol (2008) 1.11
Human papillomavirus in early laryngeal carcinoma. Laryngoscope (2009) 1.10
Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy (2011) 1.10
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun (2008) 1.09
Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer (2011) 1.09
Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions. Int Immunol (2012) 1.08
Human papillomavirus-related squamous cell carcinoma of the oropharynx: a comparative study in whites and African Americans. Arch Otolaryngol Head Neck Surg (2011) 1.07
Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother (2012) 1.07
B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol (2012) 1.05
Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol (2009) 1.05
Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med (2010) 1.05
Undifferentiated carcinoma of the oropharynx: a human papillomavirus-associated tumor with a favorable prognosis. Mod Pathol (2011) 1.04
The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J Immunol (2009) 1.04
Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis (2005) 1.03
Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. Am J Health Syst Pharm (2011) 1.01
Arrested natural killer cell development associated with transgene insertion into the Atf2 locus. Blood (2005) 0.99
Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A (2013) 0.99
Detection and significance of human papillomavirus, CDKN2A(p16) and CDKN1A(p21) expression in squamous cell carcinoma of the larynx. Mod Pathol (2012) 0.98
Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2009) 0.98
Murine cytomegalovirus paralyzes macrophages by blocking IFN gamma-induced promoter assembly. Proc Natl Acad Sci U S A (2003) 0.98
Merkel cell carcinoma of the head and neck. Head Neck (2011) 0.96
The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother (2007) 0.95
Magnetic resonance imaging of adrenal angiomyolipoma. J Comput Assist Tomogr (2005) 0.94
A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma. Cancer (2012) 0.94
Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother (2009) 0.93
Abscopal effect in a patient with metastatic Merkel cell carcinoma following radiation therapy: potential role of induced antitumor immunity. Arch Dermatol (2011) 0.93
Large cell neuroendocrine carcinoma of the head and neck. Oral Oncol (2011) 0.92
Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res (2012) 0.92
Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Manag (2008) 0.92
Epstein-Barr virus nuclear antigen 1 (EBNA1) protein induction of epithelial-mesenchymal transition in nasopharyngeal carcinoma cells. Cancer (2013) 0.91
Mammaglobin and S-100 immunoreactivity in salivary gland carcinomas other than mammary analogue secretory carcinoma. Hum Pathol (2013) 0.91
Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurg Focus (2014) 0.91
Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A (2014) 0.91
Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications. Eur Arch Otorhinolaryngol (2013) 0.91
Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life. Cancer (2014) 0.91
Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer (2012) 0.91
Intraosseous carcinoma of the jaws: a clinicopathologic review. Part III: Primary intraosseous squamous cell carcinoma. Head Neck (2012) 0.90
Current options in antifungal pharmacotherapy. Pharmacotherapy (2008) 0.90
Verrucous carcinomas of the head and neck, including those with associated squamous cell carcinoma, lack transcriptionally active high-risk human papillomavirus. Hum Pathol (2013) 0.90
Lymphadenoma of the salivary gland: clinicopathological and immunohistochemical analysis of 33 tumors. Mod Pathol (2011) 0.89
Community-associated methicillin-resistant Staphylococcus aureus: new bug, old drugs. Ann Pharmacother (2006) 0.89
Cancer immunoediting of the NK group 2D ligand H60a. J Immunol (2011) 0.89
A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid. Antimicrob Agents Chemother (2013) 0.89
Keratinizing-type squamous cell carcinoma of the oropharynx: p16 overexpression is associated with positive high-risk HPV status and improved survival. Am J Surg Pathol (2014) 0.89
Detection of SHV-type extended-spectrum beta-lactamase in Enterobacter isolates. J Clin Microbiol (2009) 0.89
Detection systems for carbapenemase gene identification should include the SME serine carbapenemase. Int J Antimicrob Agents (2012) 0.89
The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope (2012) 0.89